Abstract Details

Title Assessing the Concordance of CIDP Clinical Diagnosis to the 2010 EFNS/PNS and the 2021 EAN/PNS Diagnostic Criteria in a Cohort of Patients at KU Medical Center: A Pilot Study

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P7 - Poster Session 7 (8:00 AM-9:00 AM)

Poster/Presentation
Number 9-022

Objective This study assesses how many CIDP patients at University of Kansas Medical Center (KUMC) meet the 2010 and 2021 criteria and compares their clinical and electrophysiological (EDX) profiles across both.

Background Diagnostic criteria for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) have evolved to improve accuracy and consistency. The most widely used are the 2010 EFNS/PNS and the updated 2021 EAN/PNS guidelines.

Design/Methods Following IRB approval, a retrospective review of CIDP cases at KUMC (2019–2024) was conducted using electronic medical records. Data were collected via a REDCap survey including demographics, clinical features, lab results, diagnoses, and EDX studies. Clinical criteria were assessed manually; EDX criteria were calculated using a standardized formula to determine compliance with both guidelines.

Results

Of 480 flagged records, 55 were reviewed; 25 were excluded due to missing documentation or lack of CIDP diagnosis. Among 30 confirmed cases (mean age 61.1 years; 63.3% male; 80% Caucasian), 73.3% were initially diagnosed with typical CIDP, half by KU neuromuscular specialists. Final diagnosis confirmed typical CIDP in 66.7%, with 33.3% misdiagnosed.

Among confirmed cases, 75% met both 2010 and 2021 criteria. Clinical criteria were met in 80% (2010) and 90% (2021); EDX criteria in 90% (2010) and 85% (2021). Among alternative diagnoses, 10% met 2010 and 20% met 2021 criteria. Notably, 80% of non-CIDP patients met EDX criteria for both, though only one met 2010 clinical criteria and two met 2021.

Conclusions

Clinical criteria are the key discriminator for accurate CIDP diagnosis, highlighting the need to educate community neurologists to reduce misdiagnosis.

Full review of all 480 cases is planned before the AAN conference to strengthen conclusions.

Authors/Disclosures
Hussien S. Alkully, MD (King Abdulaziz University) PRESENTER	Dr. Alkully has nothing to disclose.
Mamatha Pasnoor, MD, FAAN	Dr. Pasnoor has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx BVBA. Dr. Pasnoor has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen Pharmaceutical. Dr. Pasnoor has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunovant. Dr. Pasnoor has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Pasnoor has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Annexon. Dr. Pasnoor has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Grifols. Dr. Pasnoor has received personal compensation in the range of $500-$4,999 for serving as a Consultant for amgen.
Mazen M. Dimachkie, MD, FAAN (University of Kansas Medical Center)	Dr. Dimachkie has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Dimachkie has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Octapharma. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ArgenX. Dr. Dimachkie has received personal compensation in the range of $0-$499 for serving as a Consultant for Catalyst. Dr. Dimachkie has received personal compensation in the range of $0-$499 for serving as a Consultant for Takeda. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medlink. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL Behring. Dr. Dimachkie has received personal compensation in the range of $0-$499 for serving as a Consultant for Astellas. Dr. Dimachkie has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Janssen. Dr. Dimachkie has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Dianthus. Dr. Dimachkie has received personal compensation in the range of $0-$499 for serving as a Consultant for TACT / Treat NMD. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cabaletta Bio. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clinical Neurological Society of America, Inc . Dr. Dimachkie has received personal compensation in the range of $0-$499 for serving as a Consultant for Ig Society, Inc. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abcuro. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amicus. Dr. Dimachkie has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon/Immunovant. Dr. Dimachkie has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nuvig. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ��ɫ�� (AAN). Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM). Dr. Dimachkie has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Annexon Biosciences. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AstraZeneca. Dr. Dimachkie has received personal compensation in the range of $0-$499 for serving as a Consultant for Candid Therapeutics. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Creyon Bio, Inc.. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nuvig Therapeutics. Dr. Dimachkie has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB Biopharma. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vertex Pharmaceuticals. Dr. Dimachkie has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Fortrea. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kriya Therapeutics. The institution of Dr. Dimachkie has received research support from NIH. The institution of Dr. Dimachkie has received research support from The Myositis Association. The institution of Dr. Dimachkie has received research support from Biosensics. Dr. Dimachkie has received intellectual property interests from a discovery or technology relating to health care. Dr. Dimachkie has received intellectual property interests from a discovery or technology relating to health care. Dr. Dimachkie has received intellectual property interests from a discovery or technology relating to health care. Dr. Dimachkie has received publishing royalties from a publication relating to health care. Dr. Dimachkie has received publishing royalties from a publication relating to health care.
Natalie Bartnik, DO (University of Kansas Medical Center)	Dr. Bartnik has nothing to disclose.
Omar Jawdat, MD (The University of Kansas Medical Center)	Dr. Jawdat has nothing to disclose.
Constantine Farmakidis, MD, FAAN	Dr. Farmakidis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Farmakidis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for J&J. Dr. Farmakidis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Muscular Dystrophy Association.
Matthew Varon, MD (University of Kansas Medical Center)	Dr. Varon has nothing to disclose.
Mustafa Al-Kharsan, MD (Kansas University Medical Center)	Dr. Al-Kharsan has nothing to disclose.
Long F. Davalos, MD	Dr. Davalos has nothing to disclose.

��ɫ����

��ɫ����

��ɫ��

��ɫ��